
|Videos|October 20, 2015
Q&A With Maha Radhakrishnan From Biogen: Zinbryta Looks To Bring New Tool to Multiple Sclerosis Treatent Battle
Author(s)Adam Hochron
While there are already several medications and treatments on the market for relapsing multiple sclerosis there continues to be a concerted effort to develop more in an effort to help as many patients as possible.
Advertisement
While there are already several medications and treatments on the market for relapsing multiple sclerosis there continues to be a concerted effort to develop more in an effort to help as many patients as possible.
Maha Radhakrishnan, MD, Vice Presdient of the European and Canadian medical groups at Biogen discussed the development of the new treatment option and what it could mean to patient care if approved by the regulatory bodies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI
2
Skin of Color Savvy: Mentorship in Dermatology—Building the Next Generation of Leaders
3
WAO Delphi Consensus Endorses ED05-Based Allergen Labelling
4
Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD
5






































































